Cost-effective use of 5-HT3-receptor antagonist therapy

J. Koeller, S. M. Grunberg

Research output: Contribution to journalArticle

Abstract

Clinical trials with granisetron, ordansetron, and dolasetron clearly demonstrate the appropriateness of single-dose IV therapy - a therapeutic range of 8 to 32 mg for ondansetron, 10 to 160 μg/kg for granisetron, and 0.6 to 5 mg/kg for dolasetron. Oral administration is also strongly supported at dosages of 16 to 24 mg for ondansetron, 1 to 2 mg for granisetron, and 200 mg for dolasetron whenever reimbursement covers the use of oral formulations. Dexamethasone should be added to the antiemetic regimen routinely; it can significantly increase efficacy at a small additional cost and may even allow lower doses of the 5-HT3-receptor antagonists to be used. Physician education is still needed at institutions where these drugs are prescribed in excessive dosages or on an as-needed basis. The proper use of 5-HT3-receptor antagonists clearly must be based on study findings rather than on subjective perceptions about how much drug is needed to prevent or substantially reduce emesis in patients undergoing chemotherapy. Improper use of antiemetics can easily triple the treatment costs for patients with cancer.

Original languageEnglish (US)
JournalP and T
Volume22
Issue number7 SUPPL.
StatePublished - 1997
Externally publishedYes

Fingerprint

Granisetron
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Ondansetron
Antiemetics
Costs and Cost Analysis
Pharmaceutical Preparations
Health Care Costs
Dexamethasone
Vomiting
Oral Administration
Therapeutics
Clinical Trials
Physicians
Education
Drug Therapy
dolasetron
Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

Koeller, J., & Grunberg, S. M. (1997). Cost-effective use of 5-HT3-receptor antagonist therapy. P and T, 22(7 SUPPL.).

Cost-effective use of 5-HT3-receptor antagonist therapy. / Koeller, J.; Grunberg, S. M.

In: P and T, Vol. 22, No. 7 SUPPL., 1997.

Research output: Contribution to journalArticle

Koeller, J & Grunberg, SM 1997, 'Cost-effective use of 5-HT3-receptor antagonist therapy', P and T, vol. 22, no. 7 SUPPL..
Koeller J, Grunberg SM. Cost-effective use of 5-HT3-receptor antagonist therapy. P and T. 1997;22(7 SUPPL.).
Koeller, J. ; Grunberg, S. M. / Cost-effective use of 5-HT3-receptor antagonist therapy. In: P and T. 1997 ; Vol. 22, No. 7 SUPPL.
@article{843301bbde10480a8fee34cf8db7eade,
title = "Cost-effective use of 5-HT3-receptor antagonist therapy",
abstract = "Clinical trials with granisetron, ordansetron, and dolasetron clearly demonstrate the appropriateness of single-dose IV therapy - a therapeutic range of 8 to 32 mg for ondansetron, 10 to 160 μg/kg for granisetron, and 0.6 to 5 mg/kg for dolasetron. Oral administration is also strongly supported at dosages of 16 to 24 mg for ondansetron, 1 to 2 mg for granisetron, and 200 mg for dolasetron whenever reimbursement covers the use of oral formulations. Dexamethasone should be added to the antiemetic regimen routinely; it can significantly increase efficacy at a small additional cost and may even allow lower doses of the 5-HT3-receptor antagonists to be used. Physician education is still needed at institutions where these drugs are prescribed in excessive dosages or on an as-needed basis. The proper use of 5-HT3-receptor antagonists clearly must be based on study findings rather than on subjective perceptions about how much drug is needed to prevent or substantially reduce emesis in patients undergoing chemotherapy. Improper use of antiemetics can easily triple the treatment costs for patients with cancer.",
author = "J. Koeller and Grunberg, {S. M.}",
year = "1997",
language = "English (US)",
volume = "22",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Cost-effective use of 5-HT3-receptor antagonist therapy

AU - Koeller, J.

AU - Grunberg, S. M.

PY - 1997

Y1 - 1997

N2 - Clinical trials with granisetron, ordansetron, and dolasetron clearly demonstrate the appropriateness of single-dose IV therapy - a therapeutic range of 8 to 32 mg for ondansetron, 10 to 160 μg/kg for granisetron, and 0.6 to 5 mg/kg for dolasetron. Oral administration is also strongly supported at dosages of 16 to 24 mg for ondansetron, 1 to 2 mg for granisetron, and 200 mg for dolasetron whenever reimbursement covers the use of oral formulations. Dexamethasone should be added to the antiemetic regimen routinely; it can significantly increase efficacy at a small additional cost and may even allow lower doses of the 5-HT3-receptor antagonists to be used. Physician education is still needed at institutions where these drugs are prescribed in excessive dosages or on an as-needed basis. The proper use of 5-HT3-receptor antagonists clearly must be based on study findings rather than on subjective perceptions about how much drug is needed to prevent or substantially reduce emesis in patients undergoing chemotherapy. Improper use of antiemetics can easily triple the treatment costs for patients with cancer.

AB - Clinical trials with granisetron, ordansetron, and dolasetron clearly demonstrate the appropriateness of single-dose IV therapy - a therapeutic range of 8 to 32 mg for ondansetron, 10 to 160 μg/kg for granisetron, and 0.6 to 5 mg/kg for dolasetron. Oral administration is also strongly supported at dosages of 16 to 24 mg for ondansetron, 1 to 2 mg for granisetron, and 200 mg for dolasetron whenever reimbursement covers the use of oral formulations. Dexamethasone should be added to the antiemetic regimen routinely; it can significantly increase efficacy at a small additional cost and may even allow lower doses of the 5-HT3-receptor antagonists to be used. Physician education is still needed at institutions where these drugs are prescribed in excessive dosages or on an as-needed basis. The proper use of 5-HT3-receptor antagonists clearly must be based on study findings rather than on subjective perceptions about how much drug is needed to prevent or substantially reduce emesis in patients undergoing chemotherapy. Improper use of antiemetics can easily triple the treatment costs for patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031392016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031392016&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031392016

VL - 22

JO - P and T

JF - P and T

SN - 1052-1372

IS - 7 SUPPL.

ER -